Initially, ADT typically leads to 90-95% decrease in circulating androgen levels, being complemented by a 50% decrease in intraprostatic dihydrotestosterone (DHT) and AR inhibition (30), impairing tumor cells’ survival (26, 28). This evidence concerns the gene AR and neoplasm.